Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEP Study: EC5026 in Parkinson's Disease
NCT07142044Phase 2Recruiting
- Sponsor
- EicOsis Human Health
- Start
- Nov 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of EC5026 in Parkinson's disease (PD) (3 arms), sponsored by EicOsis Human Health. Primary endpoint: Incidence of Adverse Events and Serious Adverse Events at 56 days. Started Nov 2025; status: recruiting.
02
Drugs
EC5026
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07142044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07142044.